LONDON ¿ Cambridge Antibody Technology Group plc, of Royston, Cambridgeshire, said Phase I trials of its fully human monoclonal antibody, J695, have started and that it received approval for a Phase II trial of CAT-152.
The trials of J695, which neutralizes the pro-inflammatory molecule interleukin-12, are being carried out by CAT¿s partners, BASF Pharma and the Genetics Institute (part of Wyeth-Ayerst Laboratories).
CAT-152, an anti-TGF beta 2 monoclonal antibody, is being developed for the prevention of scarring in the eye following glaucoma surgery. Four U.K. hospitals will take part in the Phase II trial. ¿ Nuala Moran